2018

September 4, 2018
Macrolide Pharmaceuticals Expands Leadership and Strengthens Expertise in Drug Development, Clinical Strategy, Finance and Business Development  Full Press Release Here

April 2, 2018
Macrolide Pharmaceuticals Appoints New President and CEO, Raises $20 Million in Investor Financing  Full Press Release Here

March 26, 2018
Macrolide Pharmaceuticals Announces Up to $6.8 Million from CARB-X to Develop Macrolide Antibiotics with Gram-Negative Activity  Full Press Release Here

March 15, 2018
Macrolide Pharmaceuticals Presents New Data on Tool to Differentiate Macrolide Antibacterial Drug by Risk of Liver Toxicity  Full Press Release Here

2017

October 5, 2017
Macrolide Pharmaceuticals Appoints Two New Board Members. Full Press Release Here

 

2016

October 24, 2016
Andrew Myers research is discussed in the Harvard Magazine article Super Drugs for Super Bugs.

June 9, 2016
Macrolide Pharmaceuticals was featured this month in Biocentury Innovations article “Building A Better Haystack”, by Selina Koch.

May 24, 2016
Macrolide Pharmaceuticals Scientific Founder Publishes New Findings in Nature About Groundbreaking Technology for Novel Macrolide Antibiotics.

2015

May 28, 2015
Macrolide was featured this month in AAAS magazine Science article “The Drug Push – fighting drug resistant bacteria”.

March 4, 2015
Macrolide Pharmaceuticals, Inc. Raises $22 Million in Series A Financing.

March 2, 2015
Antibiotic resistance is becoming a global threat.

This is a scary situation. People talk about going backward to a pre-antibiotic era where you could go in for knee replacement surgery and lose your leg, or even your life, to an infection.

Andrew Myers

Amory Houghton Professor of Chemistry and Chemical Biology, Harvard University

Partner with us

We are eager to collaborate with academic institutions and other companies who are interested in macrolide development, and anti-bacterials broadly.